Polymyxin B Injection, Powder, For Solution
Product Images NDC 0143-9461

This text appears to mention the sequence of amino acids (Dab, Phe, Leu, Thr) in the structure of Polymyxin B. It also indicates a structural difference between two variations of Polymyxin B molecule (R=CH3 and R=H). The text seems to be related to a chemical or pharmaceutical study of Polymyxin B variants.*

This is a description of Polymyxin B for Injection, USP, with a concentration of 500,000 units per vial. The drug is intended for hospital use and is administered via intramuscular, intravenous, or intrathecal routes. The packaging includes a warning about potential neuro-toxicity and nephrotoxicity. It is manufactured by Hikma Pharmaceuticals USA, Inc. in Berkeley Heights, NJ. Each vial contains Polymyxin B Sulfate equivalent to 500,000 Polymyxin B units. The recommended storage conditions are specified before and after reconstitution. After reconstitution, the product must be stored under refrigeration and any unused portion should be discarded after 72 hours.*

This text provides information about the dosage, warning, administration, and storage instructions for a drug containing Polymyxin B, which is used for neuro- and nephrotoxic conditions. It emphasizes that the drug should be administered intramuscularly, intravenously, or intrathecally in hospitalized patients only. The storage requirements include refrigeration after reconstitution. The drug is manufactured by Hikma Pharmaceuticals USA and is recommended for hospital use only. Each vial contains Polymyxin B Sulfate equivalent to 500,000 polymyxin B units, and any unused portion should be discarded after 72 hours.*